Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Breakthrough, Potential Blockbuster Product for High Risk Cardiovascular Patients
09-Jan-2008 -
Genzyme Corp. and Isis Pharmaceuticals, Inc. announced that they have entered a major strategic alliance in which Genzyme will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high risk cardiovascular patients that utilizes novel antisense technology. As part of the ...
cholesterol
Genzyme
hypercholesterolemia
+4